

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 4173

HOUGHTON ET AL.

Examiner: Benjamin J. Packard

APPLICATION NO: 10/530,618

FILED: FEBRUARY 23, 2006

FOR: USE OF IMATINIB (GLIVEC, STI-571) TO INHIBIT BREAST  
CANCER RESISTANCE PROTEIN (BCRP)-MEDIATED  
RESISTANCE TO THERAPEUTIC AGENTS

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450


NOTICE OF APPEAL

Sir:

Applicants hereby appeal to the Board of Patent Appeals and Interferences from the Office Action dated August 20, 2008 finally rejecting claims 25-27.

- ☒ Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$540 for payment of the appeal fee. An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.
- ☐ The appeal fee was paid in a previous appeal herein. The examiner re-opened prosecution prior to any decision by the Board of Patent Appeals and Interferences. No fee is now due.
- ☒ Enclosed is a Petition for Extension of Time.

Respectfully submitted,



George R. Dohmann  
Attorney for Applicants  
Reg. No. 33,593

Novartis Pharmaceuticals Corp.  
Patents Pharma  
One Health Plaza, Building 101  
East Hanover, NJ 07936-1080  
(862) 778-7824

Date: 2/14/09